×
GSK Basic EPS 2010-2024 | GSK
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
GSK basic eps for the twelve months ending September 30, 2024 was
$1.56
, a
64.25% decline
year-over-year.
GSK annual basic eps for 2023 was
$0.003B
, a
67.08% decline
from 2022.
GSK annual basic eps for 2022 was
$0.009B
, a
205.15% increase
from 2021.
GSK annual basic eps for 2021 was
$0.003B
, a
18.8% decline
from 2020.
View More
GSK Basic EPS 2010-2024 | GSK
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
GSK annual basic eps for 2023 was
$0.003B
, a
67.08% decline
from 2022.
GSK annual basic eps for 2022 was
$0.009B
, a
205.15% increase
from 2021.
GSK annual basic eps for 2021 was
$0.003B
, a
18.8% decline
from 2020.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$158.3B
Bristol Myers Squibb (BMY)
$119.4B
Vertex Pharmaceuticals (VRTX)
$116.1B
Gilead Sciences (GILD)
$112.4B
CSL (CSLLY)
$87.2B
Regeneron Pharmaceuticals (REGN)
$81.1B
Argenex SE (ARGX)
$36.2B
Alnylam Pharmaceuticals (ALNY)
$31.6B
BioNTech SE (BNTX)
$27.1B
Biogen (BIIB)
$23B
Illumina (ILMN)
$22.2B
BeiGene (BGNE)
$18.6B
Moderna (MRNA)
$15.8B
Incyte (INCY)
$13.8B
Genmab (GMAB)
$13.7B
Insmed (INSM)
$13.1B
BioMarin Pharmaceutical (BMRN)
$12.2B
Bio-Techne Corp (TECH)
$11.3B
Vaxcyte (PCVX)
$11B
Sarepta Therapeutics (SRPT)
$10.9B
Exelixis (EXEL)
$10.2B
Exact Sciences (EXAS)
$9.8B
QIAGEN (QGEN)
$9.8B
Revolution Medicines (RVMD)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$9.3B
Intra-Cellular Therapies (ITCI)
$9.1B
Repligen (RGEN)
$8B
Ascendis Pharma (ASND)
$7.9B
Legend Biotech (LEGN)
$7.5B